MGNX — MacroGenics Income Statement
0.000.00%
Last trade - 00:00
- $976.57m
- $746.76m
- $58.75m
- 20
- 16
- 90
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 64.2 | 105 | 77.4 | 152 | 58.7 |
Cost of Revenue | |||||
Gross Profit | — | — | 74.8 | 145 | 50.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 241 | 236 | 280 | 273 | 76.1 |
Operating Profit | -177 | -131 | -203 | -121 | -17.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -152 | -130 | -202 | -120 | -9.06 |
Net Income After Taxes | -152 | -130 | -202 | -120 | -9.06 |
Net Income Before Extraordinary Items | |||||
Net Income | -152 | -130 | -202 | -120 | -9.06 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -152 | -130 | -202 | -120 | -9.06 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.16 | -2.47 | -3.37 | -1.95 | -2.58 |